An update on the safety of nivolumab for the treatment of advanced melanoma

Abstract

Introduction: Due to its unique mechanism of action as an immune checkpoint inhibitor, nivolumab has high antitumor activity, but at the same time this mechanism is responsible for immune-related adverse events that may limit patients' safety and therapy continuation. Areas covered: Long-term safety of nivolumab including 5-year follow-up, safety of nivolumab treatment after ipilimumab therapy, safety of nivolumab in challenging subgroups (elderly, patients with brain metastases, patients with autoimmune disorders), safety of nivolumab in with rare melanoma subtypes (including mucosal melanoma), as well as specificity of AEs reported for nivolumab treatment in melanoma patients in comparison to other cancer types and other immunotherapy molecules, and impact of AEs on response rates and PFS on nivolumab treatment are discussed. Expert opinion: Search for biomarkers that would help us to identify patient populations that may suffer from severe nivolumab toxicity could help in selecting patients that should not be treated with this type of therapy. Novel combinations and immunotherapy drugs including use of NKTR-214 (IL-2 pathway), lymphocyte-activation gene 3 (LAG-3), local injections of talimogene laherparepvec (T-VEC), or systemic use of T-cell receptors agonists such as OX40, CD137, ICOS-1, could provide regimens with limited toxicity and higher activity.

Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

“…In most of the referred studies, LIT has been performed at a single time point. However, in clinical cancer settings, systemic immunotherapy is given at repeated intervals, typically every 2–3 weeks depending on tumor type, patient performance status, side effects and tumor response [ 71 ]. Aiming to mimic clinical treatment settings, three murine studies applied nanoparticles as part of a LIT strategy, obtaining tumor shrinkage, tumor immunity as well as increased survival.…”

Evaluation of the roles and regulatory mechanisms of PD-1 target molecules in NSCLC progression

“…Nivolumab is the PD-1 inhibitor that binds to PD-L1 to the surface of T cells to block the immunosuppressive signaling pathway triggered by PDL-1/2 and restore the anti-tumor function of T cells. Currently, nivolumab is used to treatment the patients with unresectable or metastatic melanoma and advanced lung squamous cell carcinoma (LUSC) and show the safe and effective therapeutic effect (6)(7)(8)(9). For example, compared with the cytotoxic T-cell antigen-4 (CTLA-4) blocker ipilimumab, nivolumab has sustained recurrence-free survival benefits in patients with stage IIIB-C or IV melanoma after surgery.…”

Nivolumab for the Treatment of Advanced Pediatric Malignancies

“…Nivolumab is a human IgG4 monoclonal antibody that binds to programmed death 1 (PD-1) receptor, and as a result it blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. Binding of the PD-1 ligands to the PD-1 receptor located on T lymphocytes surface, inhibits the proliferation of T cells and the production of cytokines (2). Immunotherapy with nivolumab is based on blockade of immune checkpoints, i.e.…”